10X Genomics, Inc.:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:10X Genomics, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10978
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
10X Genomics, Inc. (10X Genomics) is engaged in developing an innovative genomics platform. The company’s product pipeline comprises of chromium controller, single cell ATAC sequencer and single cell with barcode technology. It offers single cell gene expression, single cell immune profiling, single cell CNV, genome sequencing, exome sequencing, de novo assembly applications. 10X Genomics sell the products under the brand name Chromium. The company offers its services in the field of research, which include cancer research, genetic health, agrigenomics and population genetics. It markets the products through distributors. The company operates in the US and the Netherlands. 10X Genomics is headquartered in Pleasanton, California, the US.

10X Genomics, Inc. – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
10X Genomics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
10X Genomics, Inc., Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
10X Genomics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
10X Genomics, Inc., Medical Devices Deals, 2012 to YTD 2018 8
10X Genomics, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
10X Genomics, Inc., Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
10x Genomics Raises USD50 Million in Series D Venture Financing 10
10X Genomics Raises USD55.5 Million in Series B Financing 12
Epinomics Secures Venture Funding 13
Partnerships 14
10x Genomics Enters into Partnership with BioLegend and Immudex 14
10X Genomics, Inc. – Key Competitors 15
10X Genomics, Inc. – Key Employees 16
10X Genomics, Inc. – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Corporate Communications 18
Jun 14, 2018: 10x Genomics Names Jean Philibert As Chief People Officer 18
Aug 23, 2017: 10x Genomics Appoints Mathai Mammen, M.D., Ph.D. to Its Board of Directors 19
Feb 09, 2017: 10x Genomics Bolsters Commercial Leadership with the Appointment of Bradford J. Crutchfield as Chief Commercial Officer 20
Legal and Regulatory 21
Nov 14, 2018: Bio-Rad and the University of Chicago win patent infringement case against 10X Genomics related to droplet microfluidics technologies 21
Jan 20, 2017: 10x Genomics Invalidates RainDance Technologies Patent 22
Product News 23
Jun 20, 2018: 10x Genomics Extends their Application Portfolio with the Launch of Single Cell Mouse Immune Profiling Solution 23
Mar 27, 2017: 10x Genomics Launches First High-Throughput Solution for Adaptive Immune System Analysis at Single-Cell Resolutio 24
Feb 13, 2017: 10x Genomics Launches Comprehensive Software Suite for Single-Cell RNA-seq Data Analysis and Visualization 25
Other Significant Developments 26
Oct 18, 2017: 10x Genomics Enables High-Volume Studies by Providing More Affordable Solutions for Whole Genome and Exome Analysis 26
Oct 17, 2017: Intermountain Healthcare Announces Precision Health Research Endeavors with 10x Genomics 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
10X Genomics, Inc., Pharmaceuticals & Healthcare, Key Facts 2
10X Genomics, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
10X Genomics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
10X Genomics, Inc., Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
10X Genomics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
10X Genomics, Inc., Medical Devices Deals, 2012 to YTD 2018 8
10X Genomics, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
10x Genomics Raises USD50 Million in Series D Venture Financing 10
10X Genomics Raises USD55.5 Million in Series B Financing 12
Epinomics Secures Venture Funding 13
10x Genomics Enters into Partnership with BioLegend and Immudex 14
10X Genomics, Inc., Key Competitors 15
10X Genomics, Inc., Key Employees 16
10X Genomics, Inc., Other Locations 17
10X Genomics, Inc., Subsidiaries 17

List of Figures
10X Genomics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
10X Genomics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
10X Genomics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
10X Genomics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
10X Genomics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
10X Genomics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
10X Genomics, Inc., Medical Devices Deals, 2012 to YTD 2018 8

★海外企業調査レポート[10X Genomics, Inc.:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Royal FrieslandCampina N.V.:企業のM&A・事業提携・投資動向
    Royal FrieslandCampina N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Royal FrieslandCampina N.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Cardiatis SA:製品パイプライン分析
    Summary Cardiatis SA (Cardiatis) is a medical device company that develops a multilayer technology platform for endovascular aneurysm. The company offers a three dimensional multilayer braided stent system for endovascular aneurysm repair. Its multilayer flow modulator include aortic, peripheral, bi …
  • OmniComm Systems Inc (OMCM)-医療機器分野:企業M&A・提携分析
    Summary OmniComm Systems Inc (OmniComm) is a web-based electronic data capture and eClinical software and services providing company. It provides web-based applications to pharmaceutical, biotech and medical device companies. The company’s solutions allow clinical trial sponsors and investigative si …
  • Korea Electric Power Corp (015760):電力:M&Aディール及び事業提携情報
    Summary Korea Electric Power Corp (KEPCO) is an integrated electric utility. It generates, transmits, and distributes electricity. The company produces electricity using nuclear, thermal, renewable, and other sources. Through power purchase agreements with independent power producers, KEPCO procures …
  • Humanigen Inc (HGEN):製薬・医療:M&Aディール及び事業提携情報
    Summary Humanigen Inc (Humanigen), formerly KaloBios Pharmaceuticals Inc is a biopharmaceutical company that develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company provides Ifabotuzumab(anti-EphA3) and Lenzilumab(anti-GM-CSF) recombinant monoclonal antibodi …
  • Reata Pharmaceuticals Inc (RETA):製薬・医療:M&Aディール及び事業提携情報
    Summary Reata Pharmaceuticals Inc (Reata) is a clinical-stage biopharmaceutical company that develops innovative medicines for the treatment of serious and life-threatening diseases. The company’s clinical candidates include bardoxolone methyl and omaveloxolone, which target Nrf2, a transcription fa …
  • TETRA Technologies Inc (TTI):企業の財務・戦略的SWOT分析
    Summary TETRA Technologies Inc (TETRA) is an oil and gas company that offers completion fluids and associated products and services. The company’s services comprise compression services, fluid, filtration and tools services, offshore services, production testing, rig cooling services, technology cen …
  • Sarovar Hotels Private Limited:企業の戦略・SWOT・財務情報
    Sarovar Hotels Private Limited - Strategy, SWOT and Corporate Finance Report Summary Sarovar Hotels Private Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • RPC Group PLC:企業の戦略・SWOT・財務情報
    RPC Group PLC - Strategy, SWOT and Corporate Finance Report Summary RPC Group PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Whiting Petroleum Corp (WLL):企業の財務・戦略的SWOT分析
    Whiting Petroleum Corp (WLL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Rothschild Bank AG:企業の戦略・SWOT・財務情報
    Rothschild Bank AG - Strategy, SWOT and Corporate Finance Report Summary Rothschild Bank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Costco Wholesale Corporation (COST):企業の財務・戦略的SWOT分析
    Costco Wholesale Corporation (COST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • HeartSine Technologies LLC:企業の戦略的SWOT分析
    HeartSine Technologies LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Saras S.p.A. (SRS):電力:M&Aディール及び事業提携情報
    Summary Saras S.p.A. (Saras) is crude oil refiner and operates refining, marketing, power generation and wind power businesses. The company’s major refinery is Sarroch refinery, on the Southwestern coast of Sardinia. Saras is also active in the production and sale of electricity, and offers industri …
  • Dermira Inc (DERM)-医療機器分野:企業M&A・提携分析
    Summary Dermira Inc (Dermira) is a bio-pharmaceutical company which concentrates on the development and commercialization of novel therapies for the treatment of chronic skin conditions. The company concentrates on developing drugs for the treatment of diseases such as psoriasis, hyperhidrosis, atop …
  • Rox Resources Limited:企業の戦略・SWOT・財務情報
    Rox Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Rox Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • NXT Energy Solutions Inc (SFD):企業の財務・戦略的SWOT分析
    Summary NXT Energy Solutions Inc (NXT Energy), formerly Energy Exploration Technologies Inc is an oilfield service company that offers geophysical services to the upstream oil and gas industry. The company provides Stress Field Detection (SFD) a patent pending gravity-based instrument that provides …
  • The Real Good Food Company plc:戦略・SWOT・企業財務分析
    The Real Good Food Company plc - Strategy, SWOT and Corporate Finance Report Summary The Real Good Food Company plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Regeneron Pharmaceuticals Inc (REGN):企業の財務・戦略的SWOT分析
    Regeneron Pharmaceuticals Inc (REGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • JGC Holdings Corp (1963)
    JGC Holdings Corp (1963) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company

◆H&Iグローバルリサーチ株式会社のお客様(例)◆